Abstract:Essential tremor (ET) is a progressive, chronic, neurodegenerative disease. The aetiology of ET is not well understood. A previous study showed that dysfunction of the microbiota-gut-brain axis might lead to neurological disease, and increasing evidence indicates a potential bidirectional relationship between gut microbiota and neurological disease. For example, gut microbiota is involved in motor deficits, microglia activation, and pathology, which play important roles in the development of Parkinson’s disease. Exchanging gut microbiota can reduce the expression of brainderived neurotrophic factor in the brain. Faecal microbiota transplantation (FMT) is a microbiota-targeted therapy. Several case reports have described the therapeutic effects of FMT in patients with neuropsychiatric disorders, such as epilepsy, and autism. However, the effect of FMT on ameliorating ET remains elusive. Here, we report the first case of using FMT to achieve remission of intestinal and neurological symptoms. In May 2017, a 75-year-old woman with a 7-year history of ET was recruited by the Department of Gastroenterology at the First Affiliated Hospital of Guangdong Pharmaceutical University. A month before her recruitment, the patient had been diagnosed with irritable bowel syndrome (IBS) based on symptoms of abdominal pain and diarrhoea. To confirm the patient’s suitability for FMT, endoscopy was performed, and the results indicated chronic non-atrophic gastritis (moderate, antrum) and chronic rectal mucosal inflammation. Abdominal computed tomography did not indicate any organic lesion. Hydrogenand methane-based breath tests were positive for small intestinal bacterial overgrowth, which indicated the dysbiosis of the intestinal microbiota. The patient’s nutrition was generally balanced, and there was no vitamin deficiency. Based on these results and clinical symptoms, the patient was administered the first FMT course through a nasojejunal tube under anaesthesia on 31 May 2017 (dose: 200 mL once a day on three consecutive days) after the signing of the informed consent. The stool was obtained from a young healthy donor who had undergone a comprehensive medical examination and psychological tests. After that, the fresh faecal microbiota was prepared within 2 h by using an automatic purification system (GenFMTer; FMT Medical, Nanjing, China) in our Intelligent Fecal Microbiota Separation Center and brought to the inpatient ward for immediate transplantation. The second day, the patient happily told the doctor that the frequency of defecation had significantly decreased and that she had experienced relief in her abdominal pain symptoms. The patient subsequently began her second, third, and fourth FMT cycles on 31 July 2017, 9 October 2017, and 17 January 2018 after the signing of the informed consent (Fig. S1), respectively. Interestingly, the tremor of the head and upper limbs significantly decreased after the second cycle of FMT. Based on these promising clinical improvements, we encouraged her to stop clonazepam and undergo another two cycles of FMT treatments (i.e. the third and fourth cycles), which she did with informed consent. The improvement in ET after FMT was evidenced by a decrease in the Tremor Research Group Essential Tremor Rating Assessment Scale score from 5.5 to 1.0 (Table 1). Since the patient completed the fourth cycle, she has not experienced any recurrence of ET (Video S1). The key clinical and laboratory parameters before and after the FMT are shown in Table 1. Our results showed that the IBS Severity Scoring System score dropped from 400 to 200 points after the second FMT treatment. Total bilirubin rose to a normal level after the first cycle of FMT and remained normal after the fourth. Indirect bilirubin increased to near the normal range after the second cycle of FMT. The albumin/globulin ratio, an indicator of liver function, doi:10.1111/psyg.12583 PSYCHOGERIATRICS 2020; 20: 796–798

Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis

Effect of fecal microbiota transplantation on patients with sporadic amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial

FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis

Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis: Clinical Protocol and Evaluation of Microbiota Immunity Axis

Intestinal microbiota composition in patients with amyotrophic lateral sclerosis: establishment of bacterial and archaeal communities analyses.

Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease with Fecal Microbiota Transplantation: A Pilot Study

Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis

Potential Role of Gut Microbiota in ALS Pathogenesis and Possible Novel Therapeutic Strategies

Probiotics and microbial metabolites maintain barrier and neuromuscular functions and clean protein aggregation to delay disease progression in TDP43 mutation mice

IDDF2021-ABS-0212 Fecal Microbiota Transplantation Ameliorates Experimental Colitis by Regulating Autophagy

Fecal Microbiota Transplantation for Parkinson's Patients with Constipation: A Pilot Clinical Trial

Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance

Fecal microbiota transplantation from HUC-MSC-treated mice alleviates acute lung injury in mice through anti-inflammation and gut microbiota modulation

Alterations in Nasal Microbiota of Patients with Amyotrophic Lateral Sclerosis

Faecal Microbiota Transplantation Simultaneously Ameliorated Patient's Essential Tremor and Irritable Bowel Syndrome

Fecal Microbiota Transplantation Promotes Functional Recovery in Mice with Spinal Cord Injury by Modulating the Spinal Cord Microenvironment

Brain-Gut-Microbiota Axis in Amyotrophic Lateral Sclerosis: A Historical Overview and Future Directions

Fecal Microbiota Transplantation Alleviated Alzheimer’s Disease-Like Pathogenesis in APP/PS1 Transgenic Mice

Efficacy and safety of fecal microbiota transplantation for the treatment of chronic functional constipation in the elderly

The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis

Fecal Microbiota Transplantation Modulates the Gut Flora Favoring Patients With Functional Constipation